List of Restasis drug patents
Restasis is owned by Allergan.
Restasis contains Cyclosporine.
Restasis has a total of 10 drug patents out of which 0 drug patents have expired.
Restasis was authorised for market use on 23 December, 2002.
Restasis is available in emulsion;ophthalmic dosage forms.
Restasis can be used as increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)., increase tear production in patients with keratoconjunctivitis sicca (dry eye)..
The generics of Restasis are possible to be released after 11 May, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8648048 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8633162 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US9248191 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8685930 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8629111 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8642556 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8292129 | ALLERGAN | Dispensing device |
Feb, 2031
(8 years from now) | |
| US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(9 years from now) | |
| US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(11 years from now) | |
| US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(11 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic